+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
ID07565103

Phase III Study of SUM-191 Eye Drops to Test Safety and Effectiveness in Healthy Adults and Adults with Bacterial Conjunctivitis

Led by Senju USA, Inc. · Updated on 2026-06-30

426

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a seamless Phase III trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SUM-191. The study includes healthy participants in Parts 1 and 2 and participants with bacterial conjunctivitis in Part 3. The trial is randomized, double-masked, placebo-controlled, and involves multiple centers to assess both single and multiple-dose effects. In Part 1, participants receive a single topical dose of SUM-191 or placebo. In Part 2, participants receive topical doses three times daily for 6 days. Part 3 also involves participants with bacterial conjunctivitis receiving SUM-191 or placebo topically three times daily for 6 days. The study compares SUM-191 against placebo across these parts to evaluate safety and effectiveness. Participants will have safety assessments including monitoring adverse events from Day 1 through Day 7 in Part 1 and through Day 14 in Part 2. For Part 3, clinical cure and bacterial eradication will be evaluated on Day 7 or 8, with early assessments on Day 3 or 4. Participants undergo clinical evaluations, laboratory tests, and eye exams. The study spans from screening through treatment and follow-up, with continuous monitoring of adverse events and treatment response.

CONDITIONS

Brief Title

Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

Research Team

M

Mizue Takahara

S

Satoshi Yamamoto

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here